Health

Retatrutide cut knee pain up to 75.8% in Phase 3, and the fine print matters

Lilly's first pivotal data for its triple-agonist drug lands at ACR this weekend just as Novo halves Wegovy's list price. The race has split between outcomes and price, and Lilly's headline percentages were never pre-specified.

Vincent JiangVincent Jiangfour-minute read
Share
David Ricks, chief executive of Eli Lilly, speaking at an event in Richmond, Virginia, September 2025
1 / 6Slide 1 of 6
Eli Lilly chief executive David Ricks. Lilly's first pivotal retatrutide data lands at the ACR meeting this weekend.

Knee pain fell by three quarters, and 1 in 8 patients ended the trial pain-free

Eli Lilly+0.86% — Eli Lilly, up 0.86 percent today published its first pivotal retatrutide data on November 5, one day before the American College of Rheumatology's annual meeting opens in Orlando on November 6 1. Retatrutide is Lilly's investigational once-weekly injection that activates three hormone receptors at once: GIP, GLP-1 and glucagon, the two hooks behind its tirzepatide drugs plus a third lever 1. It cannot be sold or marketed yet; the molecule remains investigational 1.

In TRIUMPH-4, a 68-week Phase 3 trial in adults with knee osteoarthritis and obesity, pain on the WOMAC scale, a standard osteoarthritis questionnaire, fell by up to 4.5 points, 75.8% from a 6.0 baseline, and more than 1 in 8 patients ended the trial reporting no knee pain 1.

In the 80-week TRIUMPH-1 trial, pain fell up to 4.3 points (73.1%), with more than 1 in 6 ending pain-free 1. Those "up to" percentages are post-hoc slices; the pre-specified means are lower, and the plenary showing the full dataset lands Sunday November 8 at 11:15 a.m 1. EST 1.

The stakes: a $24.4 billion quarter against a halved Wegovy price

The commercial context is a market splitting in two. Lilly's third-quarter revenue reached $24.4 billion, up 39% 2, and full-year guidance rose to $91 billion to $92 billion 3. With about 80% of knee osteoarthritis patients carrying obesity or overweight 1, Lilly is pitching an obesity drug into orthopedic pain, not just weight.

Novo Nordisk+1.62% — Novo Nordisk, up 1.62 percent today answered with price: Wegovy's US list price drops about 50% to $675 a month from January 1, and the Wegovy pill pulled in $810 million in the third quarter, up 53% from the second 4. Novo claims 80% of new oral GLP-1 starts; Lilly says its rival pill, Foundayo, took 40% 2.

The fine print: the headline percentages were never pre-specified

Lilly's own endnote states that percent change in the WOMAC pain score was not pre-specified and was estimated from a post-hoc analysis 1. The peer-reviewed TRIUMPH-1, published in NEJM on October 29, shows the mean: at the top 12 mg dose, pain fell 3.6 points versus 1.9 on placebo, a 61.6% reduction, with 25% weight loss 5. The release's "up to" figures are the most flattering slice of each trial, and the 75.8% and 73.1% in the first section above are that same post-hoc metric 5.

The psoriatic arthritis numbers carry the same caution. The 52-week comparison of 43.7% ACR50, the standard rheumatology bar for at least 50% improvement, for Taltz, Lilly's immunology drug, plus Zepbound versus 15.7% on Taltz alone, is exploratory with no multiplicity control 1.

Peer-reviewed TRIUMPH-1: 3.6 points of pain relief at the top dose, 1.9 on placebo

The peer-reviewed mean at 12 mg is 3.6 points; the release headline says up to 4.3

0 pts1 pts2 pts3 pts4 ptsPlacebo1.9 pts4 mg3.2 pts9 mg3.5 pts12 mg3.6 ptsLilly's release: up to 4.3 pts
Data
Value
Placebo1.9 pts
4 mg3.2 pts
9 mg3.5 pts
12 mg3.6 pts
Mean reduction in WOMAC knee-pain subscale score, in points, over 80 weeks in TRIUMPH-1, a Phase 3 trial of 2,339 adults with obesity and knee osteoarthritis, as published in NEJM and reported by Healio on October 29, 2026. The annotation shows the 'up to 4.3 points' figure from Lilly's November 5 ACR release, whose percent change was post-hoc. Source: Healio [5]; Lilly release [1].5,1

Novo's counter: 8 million prescriptions and a 30% price slide

Novo's pill has filled 8 million cumulative prescriptions since its January launch 24. Its 80% share claim leans on telehealth channels such as Hims & Hers that do not report to IQVIA−2.21% — IQVIA, down 2.21 percent as of its last quote 2. "Those companies do not share their data with IQVIA," said Novo CEO Mike Maziar Doustdar, who says IQVIA covers only 65% of Novo's scripts 2. Lilly's 40% rests on IQVIA 2. Neither number is audited 2.

A 30% price slide, and the operating-room argument

Novo's share claim also sits beside erosion: net Wegovy price fell 30.35% in the quarter 6. Foundayo booked $184 million in third-quarter sales, short of analyst expectations 3. A function-priced drug also walks into an argument orthopedists are already having: a June database study found three years on Wegovy or Zepbound was associated with about 5 fewer knee replacements per 100 people over 8 years, out of roughly 800,000 US knee replacements a year, though it is observational and cannot prove the drugs caused it 7.

"Anything that reduces pain, including weight loss, can defer or avoid an operation without changing the underlying arthritis at all," as Stanford orthopedic surgeon Derek Amanatullah put it 7.

The share war: Novo claims 80% of new oral starts, Lilly claims 40% for Foundayo

Neither Q3 share claim is audited: telehealth scripts sit outside IQVIA's count

0%20%40%60%80%Wegovy pill, Q165%Wegovy pill, Q380%Foundayo, Q340%
Data
Value
Wegovy pill, Q165%
Wegovy pill, Q380%
Foundayo, Q340%
Share of new-to-brand prescriptions in the US oral GLP-1 obesity market as claimed by each company, in percent. Both Q3 figures are unaudited company claims on different measurement bases: Novo says telehealth channels sit outside IQVIA's count, while the Q1 Wegovy figure of 65% is IQVIA-based. The dispute over how much of each company's scripts IQVIA actually covers, Novo says 90 to 95% of Lilly's scripts but only 65% of its own, is the crux of the share war. Sources: BioSpace [2]; Yahoo Finance [6].2,6

What to watch on Sunday

Three tells decide the next leg. Whether the full TRIUMPH-4 dataset shown at the plenary holds up the post-hoc percentages 1. Whether Lilly files retatrutide on a function claim rather than weight alone, which is what a payer would have to underwrite. And whether Novo's January price cut holds its share once Foundayo reaches more pharmacies 4.

Retatrutide cannot be sold yet, and a Phase 3 readout is not a coverage decision 1. But the first non-weight indication has printed: Novo is cutting price to win patients, and Lilly just printed data meant to win payers.

Get Health by email, free

AI in medicine, pharma and biotech. In our daily email, every weekday.

Loading LLY

Reader comments

0 comments

    More in Health

    All in this topic →

    Health

    Globus Medical director Tobin sold his entire stake for $3.1 million five days after a guidance cut

    James Tobin's November 10 sale left him with zero shares and zero options in Globus Medical, with no trading plan, five days after the company cut its 2026 revenue outlook by up to $130 million. The board's answer was a $500 million buyback increase.

    Health

    Molina Healthcare's CFO lays out a path to $9.50 EPS in 2027, on $4 of fixes not yet earned

    Molina's finance chief added $4 of "embedded earnings" to a $5.25 floor for 2027, assuming no recovery at all in Medicaid margins. Guidance, and the test of each dollar, arrives in February.

    Health

    Hims & Hers grew revenue 49% to $890 million, lost $33 million, and cut its 2026 profit outlook a third time

    Revenue grew 49% and the quarter still lost money, because selling Lilly's and Novo's branded weight-loss drugs books the full price without keeping it. Hims shareholders are paying for the pivot; Lilly gains a channel it barely needs.

    Health

    ACP licenses its guidelines to OpenEvidence for an undisclosed price

    The largest US medical society's guidance moves into a free, ad-funded AI valued at $15 billion, and neither side named the fee. For listed readers, the test is Wolters Kluwer's UpToDate renewals at February 2027 results.

    Health

    FDA orders NAION vision-loss warning on every GLP-1 label; Novo Nordisk up 2.65%, Eli Lilly up 4.28%

    The FDA's class-wide vision-loss warning on the world's biggest drug franchise rests on ten probable cases against five among placebo patients; Novo Nordisk and Eli Lilly rose on the news, and hundreds of blindness suits now hold a federal exhibit.

    Health

    Eli Lilly will file its obesity pill Foundayo for sleep apnea after a 44% cut in severity

    A 43.8% cut in breathing interruptions gives Lilly's pill a shot at a diagnosed-disease budget, and the company commits to an FDA filing by year-end. Novo Nordisk's rival outcomes strategy failed at the same heart conference.

    Subscribe to TheInference for free